Výsledky vyhledávání

Evaluation of HER2 and p53 expression in predicting response to docetaxel-based first-line chemotherapy in advanced breast cancer

Autor: G. Tartarelli, Paolo Viacava, Chiara Valsuani, Domenico Amoroso, Leonardo Martini, Andrea Camerini, O. Siclari, Andrea Cavazzana, Filomena De Luca, Cheti Puccetti, Sara Donati

Publikováno v: Journal of Experimental & Clinical Cancer Research, Vol 30, Iss 1, p 38 (2011)
Journal of Experimental & Clinical Cancer Research : CR

Background The human epidermal growth factor receptor 2 (HER2) and p53 pathways may be involved in chemotherapy sensitivity and/or resistance. We explore the value of HER2 and p53 status to foretell docetaxel sensitivity in advanced breast cancer. Me

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f866dbdecf4054dcd5f239a7a6035d20
http://www.jeccr.com/content/30/1/38

Zobrazit plný text záznamu

Sorafenib in a patient with advanced hepatocellular carcinoma and serious impairment of left ventricular function: a case report

Autor: Domenico Amoroso, G. Tartarelli, M. Rondini, Cheti Puccetti, Andrea Camerini, Maria Laura Canale, O. Siclari, S. Donati, Paolo Puccinelli, Chiara Valsuani

Publikováno v: Cases Journal

Introduction sorafenib, a tyrosine-kinase inhibitor, is widely used in the treatment of advanced hepatocellular carcinoma. Drug-related toxicities are generally mild but sorafenib, as other similar agents, may induce elevation of systemic arterial bl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::185f9f8dc0e53462653bb7e4c0f91177
https://doi.org/10.1186/1757-1626-2-9133

Zobrazit plný text záznamu

Phase II trial of single-agent oral vinorelbine in elderly (or =70 years) patients with advanced non-small-cell lung cancer and poor performance status

Autor: P. Puccinelli, C. Valsuani, M. Rondini, Domenico Amoroso, Andrea Camerini, Cheti Puccetti, G. Tartarelli, O. Siclari, F. Di Costanzo, S. Donati, Francesca Mazzoni

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology. 21(6)

Background Elderly patients with advanced non-small-cell lung cancer (NSCLC) with poor performance status (PS) are a special population requiring particular attention. Single-agent oral vinorelbine could be an attractive option. Patients and methods

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa82992323d37200b758c329e605e873
https://pubmed.ncbi.nlm.nih.gov/19914959

Zobrazit plný text záznamu

Expression of the CDK inhibitor p27kip1 and oxidative DNA damage in renal cell carcinoma

Autor: Alessandro Sgambato, Alma Boninsegna, Achille Cittadini, Giannicola Genovese, Massimo Cecchi, O. Siclari, Domenico Amoroso, Andrea Camerini, F. De Luca, C. Valsuani

Publikováno v: Journal of Clinical Oncology. 27:e16008-e16008

e16008 Background: Deregulation of the normal cell cycle is a frequent event in human tumors and plays an important role in malignant transformation. p27kip1 is a negative regulator of the G1 phase, is frequently lost in tumor cells and, in some case

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3e8f1c71bdb9463b6145e1dc635bf4b1
https://doi.org/10.1200/jco.2009.27.15_suppl.e16008

Zobrazit plný text záznamu

Phase II trial of single agent oral vinorelbine in elderly (≥70 years) patients with advanced non small cell lung cancer and poor performance status

Autor: C. Valsuani, Cheti Puccetti, M. Rondini, Andrea Camerini, P. Puccinelli, Domenico Amoroso, Sara Donati, L. Amadei, O. Siclari, G. Tartarelli

Publikováno v: Journal of Clinical Oncology. 26:19085-19085

19085 Background: Elderly patients with advanced non small cell lung cancer(NSCLC) with poor PS are a special population requiring particular attention. Single agent oral vinorelbine could be an at...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3ee04180ae6991a5c07a41b3ddfa6917
https://doi.org/10.1200/jco.2008.26.15_suppl.19085

Zobrazit plný text záznamu

Lipid lowering effect of fulvestrant in hormone-sensitive metastatic breast cancer patients

Autor: Sara Donati, G. Tartarelli, M. Vincenti, Alessandro Sgambato, V. Polla Mattiot, Domenico Amoroso, O. Garrone, Andrea Camerini, C. Valsuani, O. Siclari

Publikováno v: Journal of Clinical Oncology. 25:1085-1085

1085 Background: Fulvestrant (F) is a pure anti-estrogen agent available for the HT of post-menopausal ormone-sensitive advanced breast cancer (ABC). Aim of the study is to analyze the effect(s) of F treatment on lipid profile, endometrial mucosa and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f9acd93920ff2dbaa2ed51579f4e6fdc
https://doi.org/10.1200/jco.2007.25.18_suppl.1085

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání